SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “MOMO” to 555888 to receive our instant, reliable and free SMS alerts.

Good morning all,

PSID looks primed and ready this morning. It's already trading higher in the pre-market, and today's news could be just the catalyst we need.

PositiveID Corporation Announces Lawrence Livermore National Laboratory Evaluation of PositiveID’s FireflyDX

DELRAY BEACH, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (PSID), a life sciences company focused on detection and diagnostics, and its ExcitePCR Corporation subsidiary, announced today that Lawrence Livermore National Laboratory has completed an analysis and report of the FireflyDX real-time polymerase chain reaction (PCR) pathogen detection prototype. PositiveID and ExcitePCR have published the report on their websites.

The FireflyDX™ prototype system is designed to be a portable, fully automated, lab quality, real-time device able to process samples and detect pathogens at the point of care/point of need (POC/PON), faster and less expensively than existing devices.

“We are extremely proud to demonstrate the progress we’ve made in the development of FireflyDX, which, we believe, better positions ExcitePCR for the appropriate funding to move FireflyDX to its next stage and closer to commercialization,” stated Lyle L. Probst, CEO and President of ExcitePCR.

“The opportunity to show the FireflyDX prototype system in action and present data that validates our detection capabilities and demonstrates our ability to compete against industry-standard, lab-based equipment was a high point for the ExcitePCR team,” said Dr. Kimothy Smith, Chief Science Officer of ExcitePCR.

FireflyDX's applications include the near real-time detection of pathogenic organisms in verticle markets addressing human clinical applications, infectious diseases, and hospital acquired infections; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.

The report, which has been partially redacted due to the proprietary nature of certain content, was prepared under agreement between PositiveID and Lawrence Livermore National Laboratory. 

You can read in full at https://finance.yahoo.com/news/positiveid-corporation-announces-lawrence-livermore-130000470.html

I'll update you as the day progresses. All the best.

SmallCapMomo.com


--------------------------------------------------------------------------------------------------


Traders and Investors,

Ready for an exciting trading day ahead? You should be with this trade idea I've got for you.

It's one we've covered a few times in the past year, and its been good to us... But this time is different.

It's time to get PositiveID Corp (PSID) on your screen once again.

PSID has technically broken down, to 52 week lows no less. In fact, the chart is downright scary.

But that's great news for us traders.

You see, PSID has a LONG history of making some epic snap back bounces after being beaten down and oversold.

Just look at this chart below. PSID has been making killer moves after its been sold off.

Back in September it made a 400%+ gain, followed by an 80%+ gain. 

In November after being oversold it bounced 50%, and then in December it rallied twice - once for a 100%+ gain, and a second time for around 136%.

These gains are awesome, and because PSID has a good history of making such moves, we like the prospect of another major bounce coming its way.





It seems almost every month PSID makes a sharp move to the upside. 

With PSID trading at $0.0017, right at 52 week lows, after an aggressive sell off in recent days, and with such a tiny market cap and float of around $600k, we could potentially see a big bounce higher to come in the near term.

And let's address the elephant in the room - those short sellers. If there is any upside momentum in PSID, shorts may be scrambling to cover their positions - which could cause a major short squeeze.
 
Earlier this month, PSID announced its 2017 highlights, and projects continued 30% growth into 2018 which should get investors excited about the future. Here are some of the highlights for the Company...

• Closed strategic investment of $1.5 million in ENG Mobile Systems

• Received a $1.2 million purchase order for mobile labs from a single customer, the largest single order received since PositiveID acquired ENG

• ENG total vehicle bookings (new contracts and purchase orders signed) up 100% over prior year

• Announced a new product under development, the FireflyDX-Portable, a lightweight, real-time pathogen detection system with commercial availability slated for late 2018

• ExcitePCR’s CEO featured on BioWatch Panel at National Academies of Science, Engineering, and Medicine

• Completed development and commenced production of a Bluetooth-enabled version of the Caregiver® thermometer to connect wirelessly to patient monitoring stations

“In 2017, we executed on a number of our goals in our mobile labs and medical device businesses, while continuing to pursue our long-term vision for our FireflyDX products, which includes finding the right strategic partner to complete the testing and development of the FireflyDX-Portable and FireflyDX-Handheld,” stated William J. Caragol, PositiveID’s Chairman and CEO. “Looking ahead, as we continue to build bookings within our mobile labs business and see a more robust sales pipeline for Caregiver, we believe we can deliver growth in excess of 30% for both the 2017 fourth quarter and 2018 first quarter, with continued strength expected through the first half of 2018 and beyond.”

You can read more at https://finance.yahoo.com/news/positiveid-announces-2017-highlights-projects-130000466.html

PositiveID Corp (PSID) is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays.

PSID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems (“ENG”) subsidiary; Medical Devices, comprised of its Thermomedics subsidiary; and Molecular Diagnostics, consisting of its Firefly Dx prototype system for real-time pathogen detection.

ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ​ENG has delivered more than 1,500 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications.

Thermomedics markets the FDA-cleared Caregiver® thermometer, which is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs.

PSID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need, faster and less expensively than existing devices. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.

The Company's proprietary airborne pathogen detection system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), continuously and autonomously analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins.

PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time polymerase chain reaction (PCR) chemistry. Firefly Dx is being developed to meet the growing need in healthcare and molecular diagnostics markets by enabling hospitals, physicians and other providers to save lives and fight disease.

You can learn more about PSID at their website http://www.psidcorp.com/


According to OTCMarkets.com, PSID has a tiny market cap of around $600k and the company just recently announced strong financial performance and major achievements in 2017.

PSID has a technically oversold chart, which if history is anything to go by, we think could be ready to bounce significantly higher in the short term.

In fact, we believe based on the technical indicators and news catalysts, PSID could be a major gainer in the coming days/weeks.

Just look back at the chart above, and you'll see what I mean - PSID is a trader's dream, delivering some epic bounces higher after being sold off.

Make sure you do your DD on PSID and be ready to play.


All the best.

SmallCapMomo.com

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.